·PIB

BRIC aims at USD 300 billion Indian bioeconomy by 2030 and USD 1 trillion by 2047: Dr. Jitendra Singh

FlashcardsQuick reviseKey facts. One by one.Start →
In this note
  1. At a Glance
  2. Why in the News
  3. Background & Evolution
  4. Core Static Facts
  5. Multi-Dimensional Analysis
  6. Recent Developments (last 12-18 months)
  7. Prelims Hooks
  8. The 2030 Target Is the Easy Part; 2047 Is the Real Test
  9. The Bioeconomy Number Does Not Measure BRIC's Own Work
  10. Does One Society for All Institutes Help or Hurt Science?
  11. Who Pays and Who Approves: Gaps a Merger Cannot Close
  12. Anchors for Answers
  13. Mains Relevance
  14. Related Topics to Study Next
  15. NCERT Concepts to Revise
  16. Common Errors / Trap Areas

1. At a Glance

  • BRIC (Biotechnology Research and Innovation Council) is the single umbrella body for the autonomous research institutes of the Department of Biotechnology (DBT). The institutes share resources, collaborate on research and are governed together, while each keeps its own scientific strengths [1][2].
  • At BRIC's Fourth AGM, the government restated its bioeconomy targets: USD 300 billion by 2030 and USD 1 trillion by 2047 [1].
  • The release calls it among the first institutional integration models in the Government of India. Its stated purpose is to move research beyond publications and patents into products and enterprises [1].
  • Why it matters for UPSC: GS-III (S&T, biotechnology, growth); GS-II (institutional reform, governance). It also links to BioE3 Policy questions [1][6].

2. Why in the News

  • 21 Nov 2026: PIB release on the Fourth AGM of the BRIC Society, chaired by Dr. Jitendra Singh, at Kartavya Bhawan, New Delhi [1].
  • The AGM heard a proposal to dissolve the existing societies of the constituent autonomous institutions and merge them with BRIC, which would put governance under one Society [1].
  • It launched the BRIC Handbook of MoA, Rules, Regulations and Bye-laws and welcomed an Entrepreneur-in-Residence (EiR) programme [1].

3. Background & Evolution

  • Rationale: DBT ran many separate autonomous institutes, each with its own society. Integrating them aims at shared infrastructure, multidisciplinary research and unified governance [1][3].
  • Consolidation: DBT subsumed its 14 Autonomous Institutes into one apex body, BRIC [2]. DBT's Annual Report 2023-24 gives the count as 13, says the change was approved by the Cabinet, and describes BRIC as a registered society [3].
  • Naming: constituent institutes carry a "BRIC-" prefix, e.g. BRIC-CDFD (Hyderabad), BRIC-NABI (Mohali), BRIC-NBRC (Manesar), BRIC-NCCS (Pune), BRIC-NIPGR (New Delhi), BRIC-RGCB (Thiruvananthapuram), BRIC-THSTI (Faridabad) [3].
  • Governance documents: BRIC Bye-laws, 2025 published by DBT [5]. A consolidated Handbook of MoA, Rules, Regulations and Bye-laws was launched at the 4th AGM in 2026 [1].
  • Policy context: On 24 Aug 2024, the Union Cabinet approved the BioE3 (Biotechnology for Economy, Environment and Employment) Policy for Fostering High Performance Biomanufacturing [6]. DBT describes it as India's first policy in biotechnology and the framework for its Biomanufacturing and Biofoundry Initiative [7].
  • Administrative steps so far: the BRIC Secretariat is operational, and recruitment has started against revived scientific positions [1].

4. Core Static Facts

Item Fact
Full form Biotechnology Research and Innovation Council [1]
Parent department Department of Biotechnology, Ministry of Science & Technology [2][3]
Legal form Registered society, set up with Cabinet approval [3]
President, BRIC Society Dr. Jitendra Singh (Minister) [1]
Secretary, DBT and Director General, BRIC Dr. Rajesh S. Gokhale (same person holds both posts) [1]
Institutes subsumed 14 (PIB) [2]; 13 (DBT AR 2023-24) [3]
Bioeconomy target 2030 USD 300 billion [1]
Bioeconomy target 2047 USD 1 trillion [1]
Bioeconomy growth (as stated) From about USD 10 bn to over USD 195 bn (no base year given) [1]
Biotech startups More than 11,000 [1]
Nature Index India 1st in health sciences, 2nd in biological sciences among government institutions, for the 2nd year running [1]
Governance texts BRIC Bye-laws 2025 [5]; Handbook of MoA, Rules, Regulations and Bye-laws (2026) [1]
BioE3 approval Union Cabinet, 24 Aug 2024 [6]
BioE3 components Biomanufacturing hubs, Bio-AI hubs, Biofoundries; regenerative bioeconomy; linked to Net Zero and LiFE [6]
Allied initiatives D.E.S.I.G.N. for BioE3 Challenge (youth/schools); Entrepreneur-in-Residence; Vaibhav Connect (diaspora) [1]

Key terms

  • Research translation: taking work from the lab to the market. It needs capital, mentorship, industry partnerships, and an understanding of market and regulatory pathways [1].
  • Mission-aligned research: research priorities matched to national needs in healthcare, agriculture, animal health, advanced materials and technology platforms [1].

5. Multi-Dimensional Analysis

Economic

  • The 2030 and 2047 targets require scale in innovation, translation, industry participation and talent [1].
  • The 300 bn target is less than double the stated current figure (>195 bn) over about four years. The 1 tn target for 2047 is about five times today's level [1].
  • More than 11,000 startups exist; the EiR programme is meant to turn discoveries into startups and support scale-up [1].

Scientific / Technological

  • Shared infrastructure and multidisciplinary research across institutes are meant to cut duplication [1].
  • Priority platforms are biomanufacturing, biofoundries and Bio-AI hubs under BioE3 [1][6].
  • The Nature Index rankings show research quality. The open question is whether that quality turns into products [1].

Governance / Administrative

  • Moving from many separate societies to one Society means one MoA and one set of bye-laws, with a central Secretariat [1][5].
  • The release says other organisations have since been inspired by the model [1].
  • Risks: too much centralisation could reduce institute-level autonomy and speed. The release itself stresses that each institute keeps its distinct strengths [1].

Social

  • Mission-aligned research is directed at patients, farmers, industries and communities [1].
  • The D.E.S.I.G.N. for BioE3 Challenge mobilised school students and citizens [1].
  • Members proposed interdisciplinary work with the social sciences [1].

Environmental

  • BioE3 promotes a regenerative bioeconomy and green growth, linked to Net Zero and LiFE [6].

Human Resources / Diaspora

  • Members proposed attracting Indian scientists abroad through Vaibhav Connect [1].
  • Revived scientific positions are being filled [1].

6. Recent Developments (last 12-18 months)

  • 2025: DBT publishes the BRIC Bye-laws 2025 [5].
  • 21 Nov 2026: Fourth AGM of the BRIC Society at Kartavya Bhawan [1]. At the meeting:
  • the Handbook of MoA, Rules, Regulations and Bye-laws was launched;
  • the proposal to dissolve and merge the constituent societies was placed;
  • the Secretariat was reported as operational;
  • recruitment against revived posts was reported;
  • the EiR programme was welcomed.

  • Nature Index India: BRIC ranked 1st in health sciences and 2nd in biological sciences among government institutions, for the second consecutive year [1].

7. Prelims Hooks

  • BRIC = Biotechnology Research and Innovation Council, under DBT (not DST, not CSIR) [1][2].
  • The BRIC Society is BRIC's governing body. Its President is Dr. Jitendra Singh [1].
  • Dr. Rajesh S. Gokhale is both Secretary, DBT and Director General, BRIC [1].
  • PIB states that DBT subsumed 14 autonomous institutes into BRIC [2].
  • BRIC is a registered society set up with Cabinet approval [3].
  • Bioeconomy targets: USD 300 bn by 2030; USD 1 tn by 2047 [1].
  • India has more than 11,000 biotech startups [1].
  • The Fourth AGM of the BRIC Society was held at Kartavya Bhawan, New Delhi [1].
  • The BRIC Handbook of MoA, Rules, Regulations and Bye-laws was launched at the 4th AGM [1].
  • Vaibhav Connect was cited as a route to engage the Indian scientific diaspora [1].
  • BioE3 stands for Biotechnology for Economy, Environment and Employment. Cabinet approved it on 24 Aug 2024 [6].
  • BioE3 provides for Biomanufacturing hubs, Bio-AI hubs and Biofoundries [6].
  • Example constituents: BRIC-NBRC is at Manesar; BRIC-RGCB is at Thiruvananthapuram; BRIC-NABI is at Mohali [3].
  • The D.E.S.I.G.N. for BioE3 Challenge is a youth and school biotech innovation initiative [1].

8. The 2030 Target Is the Easy Part; 2047 Is the Real Test

  • The 'USD 10 bn' starting point now has a year: 2014
  • A PIB document says the bioeconomy grew from USD 10 billion in 2014 to USD 165.7 billion in 2024. That was 4.25% of GDP [8].
  • The India BioEconomy Report (IBER) 2026 puts it at USD 195.3 billion in 2025. That is about 4.8% of GDP, with a CAGR (average yearly growth rate) of nearly 18% [9].
  • So the '>195 bn' in the AGM release is the 2025 figure, and the note's 'no base year' trap can be closed [1][9].

  • USD 300 bn by 2030 needs only about half the recent speed

  • Going from 195.3 bn (2025) to 300 bn (2030) needs about 9% growth a year [9][1].
  • The sector has recently grown at about 18% a year [9].
  • If growth only halves, India still reaches the target. So meeting 2030 will not prove that reforms like BRIC worked.

  • USD 1 tn by 2047 is hard because the growth has to last

  • It needs about 7.7% a year, every year, for 22 years [9][1].
  • Fast growth from a small base is easy. Holding it once the sector is large is hard, and that is what the 2047 goal asks for.

  • The target is in dollars, so the exchange rate counts

  • The bioeconomy is earned and counted mostly in rupees but reported in USD.
  • If the rupee weakens, the dollar figure grows more slowly even when real output grows. A miss in 2047 could partly be a currency effect, not a science failure.

9. The Bioeconomy Number Does Not Measure BRIC's Own Work

  • The target is the size of a whole market, not what labs produce
  • The USD 195.3 bn figure is the estimated value of the whole sector. It comes from the India BioEconomy Report, not from MoSPI's national accounts (the official GDP data) [9].
  • Most of that value is made by private companies and startups, not by BRIC's government institutes.
  • So the bioeconomy can hit USD 300 bn even if no BRIC lab ever makes a product, and BRIC can do well while the market stays flat.

  • The only success measure BRIC reports is a publication ranking

  • The release names Nature Index rankings (1st in health sciences, 2nd in biological sciences) as its achievement [1].
  • Nature Index counts research papers. BRIC's own stated aim is to go beyond papers and patents to products and enterprises [1].
  • So the one number BRIC shows measures the very thing it says it wants to move beyond.

  • What should follow: DBT should publish lab-to-market numbers for each institute

  • Examples: technologies licensed, licence income, startups that came out of BRIC labs, and products cleared by regulators.
  • Without these, the AGM cannot tell if the Entrepreneur-in-Residence (EiR) programme or the merger is working [1].

10. Does One Society for All Institutes Help or Hurt Science?

  • The strongest case against the merger: power moves to the funder
  • Today each institute has its own registered society and governing body. The AGM proposal would dissolve these and merge them into one BRIC Society [1].
  • The President of that Society is the Minister. The Director General of BRIC is also the Secretary of DBT, the department that funds the institutes [1].
  • So the body that pays for the research and the body that runs the institutes become the same people. An institute loses its own board, which could say no or move quickly on its own.
  • Even the basic record is not settled: PIB says 14 institutes were merged, while DBT's own annual report says 13 [2][3].

  • What the critics get right

  • Fast-moving areas like biofoundries and Bio-AI (BioE3 priorities) need quick local decisions on hiring, buying equipment and partnering with industry [6].
  • If every such decision goes up to one central Secretariat, a single delay holds up all the institutes at once.

  • The honest answer: the merger has already fixed some real problems

  • The release reports that scientific posts which had lapsed have been revived and are now being filled, and that a common Secretariat is working [1]. A small institute with its own society found such things harder to do alone.
  • One MoA and one set of bye-laws means one set of rules for things like industry deals [1][5]. Fourteen different rulebooks gave industry fourteen different processes to deal with.

  • What decides the outcome: what the bye-laws let directors do

  • Whether autonomy survives depends on which powers the BRIC Bye-laws 2025 and the new Handbook leave with institute directors [5][1].
  • The BRIC Society should keep strategy and money at the top, and leave scientific choices, small purchases and startup tie-ups to each institute.

11. Who Pays and Who Approves: Gaps a Merger Cannot Close

  • Companies spend too little on R&D to carry lab work into products
  • PRS notes that private-sector R&D in India has been stuck at about 0.25% of GDP [10].
  • The AGM itself said that translation (taking lab work to market) needs capital, mentorship and industry partners [1].
  • Merging institutes changes how they are run. It does not bring in company money. The 11,000+ startups can grow only if investors and big buyers step in [1].

  • Approvals can be slower than the science

  • OECD finds that slow approval processes hold back biotech products. It suggests more agile (faster, more flexible) regulation plus finance tools that pull in private investment [11].
  • In India, a biotech product may need clearance under the biosafety rules (GEAC, Rules 1989) and the Biological Diversity Act. These sit outside DBT's research setup.
  • So a BRIC lab can be world-class on Nature Index and still lose years waiting for approval [1].

  • What should follow, and by whom

  • DBT and the regulators: follow the OECD approach and set clear, time-bound approval routes for BioE3 biomanufacturing products [11][6].
  • BRIC Society: link the EiR programme to shared biomanufacturing and biofoundry facilities under BioE3, so startups do not have to build their own plants [1][6].
  • Ministry of Science & Technology: aim policy at raising private R&D above the flat 0.25% of GDP, because the 2047 target cannot be met with public money alone [10][1].

12. Anchors for Answers

  • Data: India's bioeconomy was USD 195.3 bn in 2025, about 4.8% of GDP, growing at nearly 18% CAGR [9]
  • Data: It grew from USD 10 bn in 2014 to USD 165.7 bn in 2024, which was 4.25% of GDP [8]
  • Data: Private-sector R&D in India has stayed at about 0.25% of GDP [10]
  • Data (worked out): 300 bn by 2030 needs about 9% growth a year; 1 tn by 2047 needs about 7.7% a year for 22 years [9][1]
  • Report/Committee: India BioEconomy Report 2026 [9]; PRS, Demand for Grants 2024-25 Analysis: Science and Technology [10]
  • Comparison: OECD, Boosting Biotechnology Innovation through Agile Regulation and Finance Instruments: faster approvals plus finance that pulls in private money to take biotech to market [11]
  • Scheme: BioE3 Policy (2024): its biomanufacturing hubs and biofoundries are where BRIC research has to become products [6]

13. Mains Relevance

14. Related Topics to Study Next

  • BioE3 Policy (2024): the policy framework that BRIC's biomanufacturing role serves [6].
  • BIRAC: DBT's PSU for startup and industry funding, which complements BRIC on translation.
  • Anusandhan National Research Foundation (ANRF): another national-level move to consolidate and steer research funding.
  • India BioEconomy Report (IBER): the source of the annual bioeconomy figures. Editions differ, so note the year.
  • National Biopharma Mission / Genome India Project: DBT flagship missions that BRIC institutes take part in.
  • CSIR integration and reform debates: a comparable precedent for restructuring scientific institutions.
  • Biosafety regulation (GEAC, Rules 1989) and the Biological Diversity Act: the regulatory pathways that translation has to clear.
  • Nature Index: a metric for research output used in rankings.

15. NCERT Concepts to Revise

  • Bioeconomy (Economy): The 300 bn and 1 tn targets are about the size of this sector.
  • BioE3 policy (Economy): The policy framework that BRIC's biomanufacturing and biofoundry role is meant to serve.
  • Biomanufacturing (Economy): Making products with microbes and cells is where BRIC research must turn into products.
  • Startup (Economy): The note cites 11,000+ biotech startups and the Entrepreneur-in-Residence route to scale them.
  • Entrepreneurship (Economy): The EiR programme aims to turn lab discoveries into enterprises that bear market risk.
  • Governance (Polity): Merging many societies into one raises questions of centralisation, autonomy and unified governance.
  • Anusandhan National Research Foundation (Polity): Another national move to consolidate and steer research funding, comparable to BRIC.
  • Private sector (Economy): Low private R&D spending limits how far lab work can reach the market.
  • Gross Domestic Product (Economy): The bioeconomy's size is expressed as a share of GDP (4.8%).
  • Foreign exchange rate (Economy): Targets are in dollars, so a weaker rupee slows the reported figure.
  • Green growth (Economy): BioE3 links the bioeconomy to environmentally sustainable growth and a regenerative economy.
  • Economic growth (Economy): Hitting 300 bn and 1 tn needs sustained yearly growth rates.
  • BRICS (Economy): BRIC here is a DBT research council, not this country grouping, and the two are easily confused.

16. Common Errors / Trap Areas

  • BRIC vs BRICS: BRIC here is a DBT research council. It has nothing to do with the BRICS grouping of countries.
  • Number of institutes: PIB gives 14 [2]; DBT AR 2023-24 gives 13 [3]. In MCQs, prefer the PIB figure and expect options built on this gap.
  • BRIC vs BRIC Society: the Council integrates the institutes; the Society is the governing body, presided over by the Minister [1].
  • Ministry and department: BRIC is under DBT, not DST or CSIR. Dr. Gokhale holds two posts (Secretary DBT and DG BRIC) [1].
  • Bioeconomy figures: the release's "~USD 10 bn → >195 bn" has no base year [1]. Do not mix it up with IBER figures for specific years. Keep 2030 (300 bn) and 2047 (1 tn) apart.

Sources

  1. 1PIB: BRIC aims at USD 300 billion Indian bioeconomy by 2030 and USD 1 trillion by 2047 (Fourth AGM, BRIC Society), 21 Nov 2026pib.gov.in · tier 1
  2. 2PIB, Ministry of Science & Technology: DBT subsumes 14 Autonomous Institutes into apex body BRICpib.gov.in · tier 1
  3. 3DBT Annual Report 2023-24 (English) — ).pdfdbtindia.gov.in · tier 1
  4. 4DBT: Biotechnology Research and Innovation Councildbtindia.gov.in · tier 1
  5. 5DBT: BRIC Bye-laws 2025dbtindia.gov.in · tier 1
  6. 6PIB: Cabinet approves BioE3 Policy for Fostering High Performance Biomanufacturing, 24 Aug 2024pib.gov.in · tier 1
  7. 7DBT: Biomanufacturing Initiativebmi.dbtindia.gov.in · tier 1
  8. 8PIB document (Sep 2025): India's bioeconomy, USD 10 bn (2014) to USD 165.7 bn (2024), 4.25% of GDPstatic.pib.gov.in · tier 1
  9. 9PIB, Ministry of Science & Technology: India BioEconomy Report 2026, bioeconomy at USD 195.3 bn in 2025 (19 Mar 2026)pib.gov.in · tier 1
  10. 10PRS Legislative Research: Demand for Grants 2024-25 Analysis, Science and Technologyprsindia.org · tier 1
  11. 11OECD: Boosting Biotechnology Innovation through Agile Regulation and Finance Instrumentsoecd.org · tier 2

Mains Q&A on this note

NCERT concepts in this note

Also on 21 November

All 21 November articles →